Dr Valerie Cullen joined Expansion Therapeutics in May of 2021 as the Senior VP of Research at Expansion Therapeutics. She brings over 20 years of research experience in drug development for neurological disease, leading complex programs at the intersection of research, translation and clinical development. Most recently, Valerie held the role of VP, Translation and Development at Generian, where she led research on age-related and metabolic diseases. Previously, Valerie was VP at Lysosomal Therapeutics Inc where, as Program Lead, she helped advance a novel small molecule GCase activator through early development and into clinical testing for Parkinson’s Disease. She began her biotech career at Link Medicine working on Alzheimer’s Disease, and held roles of increasing responsibility at Proclara Biosciences and Aldeyra Therapeutics. Dr. Cullen graduated from University College Dublin, Ireland with a BSc (Hons) in pharmacology and won the Zeneca Prize for academic achievement. She received her Ph.D. in pharmacology from UCD and completed neurology-focused postdoctoral fellowships at King’s College, London and Harvard Medical School, where her work on Parkinson’s Disease won the Annals of Neurology Clinical Impact Prize.